
News|Articles|June 1, 2004
Early-stage breast cancer patients not receiving full benefits of chemotherapy
More than half the women suffering from early-stage breast cancer (ESBC) are at increased risk of recurrence or death because of substantial reductions-planned or unplanned-in relative dose-intensity (RDI) when treated with adjuvant chemotherapy, according to a study published in the Journal of Clinical Oncology.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
New drug class shows promise for geographic atrophy
3
HS patients on biosimilar adalimumab lose response faster than those on the original drug
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































